155 related articles for article (PubMed ID: 37776258)
41. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
[TBL] [Abstract][Full Text] [Related]
42. There Are No Magic Bullets in Hematopathology: Even Immunostains for CD20 and CD3 Can Get You Into Trouble.
Ferry JA
Adv Anat Pathol; 2018 Jan; 25(1):14-23. PubMed ID: 28914619
[TBL] [Abstract][Full Text] [Related]
43. Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior.
McClure RF; Remstein ED; Macon WR; Dewald GW; Habermann TM; Hoering A; Kurtin PJ
Am J Surg Pathol; 2005 Dec; 29(12):1652-60. PubMed ID: 16327438
[TBL] [Abstract][Full Text] [Related]
44. Best practices in diagnostic immunohistochemistry: workup of cutaneous lymphoid lesions in the diagnosis of primary cutaneous lymphoma.
Dewar R; Andea AA; Guitart J; Arber DA; Weiss LM
Arch Pathol Lab Med; 2015 Mar; 139(3):338-50. PubMed ID: 25724031
[TBL] [Abstract][Full Text] [Related]
45. Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity.
Alsuwaidan A; Pirruccello E; Jaso J; Koduru P; Garcia R; Krueger J; Doucet M; Chaudhry R; Fuda F; Chen W
Cytometry B Clin Cytom; 2019 Sep; 96(5):368-374. PubMed ID: 30734478
[TBL] [Abstract][Full Text] [Related]
46. MicroRNA profiling in canine multicentric lymphoma.
Craig KKL; Wood GA; Keller SM; Mutsaers AJ; Wood RD
PLoS One; 2019; 14(12):e0226357. PubMed ID: 31826004
[TBL] [Abstract][Full Text] [Related]
47. Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia.
McGregor S; McNeer J; Gurbuxani S
Semin Diagn Pathol; 2012 Feb; 29(1):2-11. PubMed ID: 22372201
[TBL] [Abstract][Full Text] [Related]
48. A Practical Approach to Diagnosis of B-Cell Lymphomas With Diffuse Large Cell Morphology.
King JF; Lam JT
Arch Pathol Lab Med; 2020 Feb; 144(2):160-167. PubMed ID: 31990228
[TBL] [Abstract][Full Text] [Related]
49. Driving toward precision medicine for B cell lymphomas: Targeting the molecular pathogenesis at the gene level.
Chung C
J Oncol Pharm Pract; 2020 Jun; 26(4):943-966. PubMed ID: 31964218
[TBL] [Abstract][Full Text] [Related]
50. Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.
Bogusz AM; Bagg A
Leuk Lymphoma; 2016 Sep; 57(9):1991-2013. PubMed ID: 27121112
[TBL] [Abstract][Full Text] [Related]
51. MYC rearranged B-cell neoplasms: Impact of genetics on classification.
Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C
Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071
[TBL] [Abstract][Full Text] [Related]
52. T-cell/histiocyte-rich large B-cell lymphoma: a heterogeneous entity with derivation from germinal center B cells.
Lim MS; Beaty M; Sorbara L; Cheng RZ; Pittaluga S; Raffeld M; Jaffe ES
Am J Surg Pathol; 2002 Nov; 26(11):1458-66. PubMed ID: 12409722
[TBL] [Abstract][Full Text] [Related]
53. High-grade Transformation of Low-grade B-cell Lymphoma: Pathology and Molecular Pathogenesis.
Agbay RL; Loghavi S; Medeiros LJ; Khoury JD
Am J Surg Pathol; 2016 Jan; 40(1):e1-16. PubMed ID: 26658667
[TBL] [Abstract][Full Text] [Related]
54. Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment.
Crombie JL; Armand P
Surg Oncol Clin N Am; 2020 Jan; 29(1):115-125. PubMed ID: 31757308
[TBL] [Abstract][Full Text] [Related]
55. Novel ligands for cancer diagnosis: selection of peptide ligands for identification and isolation of B-cell lymphomas.
McGuire MJ; Samli KN; Chang YC; Brown KC
Exp Hematol; 2006 Apr; 34(4):443-52. PubMed ID: 16569591
[TBL] [Abstract][Full Text] [Related]
56. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
57. Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor.
Oh YH; Park CK
J Korean Med Sci; 2006 Jun; 21(3):397-405. PubMed ID: 16778379
[TBL] [Abstract][Full Text] [Related]
58. Clinicopathogenetic significance of chromosomal abnormalities in patients with blastic peripheral B-cell lymphoma. Kiel-Wien-Lymphoma Study Group.
Schlegelberger B; Zwingers T; Harder L; Nowotny H; Siebert R; Vesely M; Bartels H; Sonnen R; Hopfinger G; Nader A; Ott G; Müller-Hermelink K; Feller A; Heinz R
Blood; 1999 Nov; 94(9):3114-20. PubMed ID: 10556197
[TBL] [Abstract][Full Text] [Related]
59. Mantle cell lymphoma.
Hankin RC; Hunter SV
Arch Pathol Lab Med; 1999 Dec; 123(12):1182-8. PubMed ID: 10583923
[TBL] [Abstract][Full Text] [Related]
60. Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas.
Montes-Moreno S; Roncador G; Maestre L; Martínez N; Sanchez-Verde L; Camacho FI; Cannata J; Martinez-Torrecuadrada JL; Shen Y; Chan WC; Piris MA
Blood; 2008 Jan; 111(1):351-8. PubMed ID: 17898315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
